Skip to main content
NCBI home page
Gut logoLink to Gut
. 1993 May;34(5):669–675. doi: 10.1136/gut.34.5.669

Oroileal transit of slow release 5-aminosalicylic acid.

H Goebell 1, U Klotz 1, B Nehlsen 1, P Layer 1
PMCID: PMC1374187  PMID: 8504969

Abstract

The predominant active anti-inflammatory moiety in chronic inflammatory bowel disease is 5-aminosalicylic acid (5-ASA). As unprotected 5-ASA is rapidly absorbed in the upper gastrointestinal tract several slow release preparations have been developed to permit passage of 5-ASA to the lower small bowel and to the colon. To investigate luminal kinetics and extent of the release of 5-ASA intraluminal concentrations and loads of this compound together with that of its main metabolite acetyl-5-aminosalicylic acid (ac-5-ASA) were studied, over 15 hours after giving the slow release preparation Salofalk at a dose of 500 mg orally together with a test meal. Plasma concentrations and urinary excretion were also measured. Six healthy volunteers swallowed an 11 lumen oroileal tube, which allowed marker perfusion, aspiration of luminal content from the duodenum, mid-jejunum, and ileum, and recording of intestinal motility. Emptying of 5-ASA into the duodenum started after emptying of the meal, together with the first phase III of interdigestive motility. Mean luminal concentrations of 5-ASA and ac-5-ASA increased continuously from duodenum (both: 15 to 30 micrograms/ml) to ileum (60 to 110 micrograms/ml and 80 to 150 micrograms/ml respectively) over three hours and decreased over the next three hours. During 10 hours after eating, 30% of the total dose passed the ileum in solution and another 10% were excreted in urine. Thus about 60% reached the colon unreleased from tablets and another 30% were in solution. The ratio of 5-ASA and ac-5-ASA in solution was about 1:1 in the duodenum and 1:1.5 to 1:2 in the more distal small intestine. The data suggest that the large quantities of intraluminal ac-5-ASA are generated in the intestinal mucosa and reach the lumen by back diffusion. The results show that most of the 5-ASA from this slow release preparation is delivered into the colon, which explains its effectiveness in ulcerative colitis. The considerable luminal concentrations already present in the distal ileum might justify therapeutic trials in Crohn's disease.

Full text

PDF
669

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allgayer H., Ahnfelt N. O., Kruis W., Klotz U., Frank-Holmberg K., Söderberg H. N., Paumgartner G. Colonic N-acetylation of 5-aminosalicylic acid in inflammatory bowel disease. Gastroenterology. 1989 Jul;97(1):38–41. doi: 10.1016/0016-5085(89)91412-1. [DOI] [PubMed] [Google Scholar]
  2. Azad Khan A. K., Piris J., Truelove S. C. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet. 1977 Oct 29;2(8044):892–895. doi: 10.1016/s0140-6736(77)90831-5. [DOI] [PubMed] [Google Scholar]
  3. Bondesen S., Schou J. B., Pedersen V., Rafiolsadat Z., Hansen S. H., Hvidberg E. F. Absorption of 5-aminosalicylic acid from colon and rectum. Br J Clin Pharmacol. 1988 Feb;25(2):269–272. doi: 10.1111/j.1365-2125.1988.tb03301.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Brogden R. N., Sorkin E. M. Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease. Drugs. 1989 Oct;38(4):500–523. doi: 10.2165/00003495-198938040-00003. [DOI] [PubMed] [Google Scholar]
  5. Christensen L. A., Fallingborg J., Abildgaard K., Jacobsen B. A., Sanchez G., Hansen S. H., Bondesen S., Hvidberg E. F., Rasmussen S. N. Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man. Aliment Pharmacol Ther. 1990 Oct;4(5):523–533. doi: 10.1111/j.1365-2036.1990.tb00499.x. [DOI] [PubMed] [Google Scholar]
  6. Evans D. F., Pye G., Bramley R., Clark A. G., Dyson T. J., Hardcastle J. D. Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut. 1988 Aug;29(8):1035–1041. doi: 10.1136/gut.29.8.1035. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Ewe K., Press A. G., Bollen S., Schuhn I. Gastric emptying of indigestible tablets in relation to composition and time of ingestion of meals studied by metal detector. Dig Dis Sci. 1991 Feb;36(2):146–152. doi: 10.1007/BF01300748. [DOI] [PubMed] [Google Scholar]
  8. Fischer C., Maier K., Klotz U. Simplified high-performance liquid chromatographic method for 5-aminosalicylic acid in plasma and urine. J Chromatogr. 1981 Oct 9;225(2):498–503. doi: 10.1016/s0378-4347(00)80303-5. [DOI] [PubMed] [Google Scholar]
  9. Fischer C., Maier K., Klotz U. Specific measurement of 5-aminosalicylic acid and its acetylated metabolite in human bile. Br J Clin Pharmacol. 1983 Feb;15(2):273–274. doi: 10.1111/j.1365-2125.1983.tb01499.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Go V. L., Hofmann A. F., Summerskill W. H. Simultaneous measurements of total pancreatic, biliary, and gastric outputs in man using a perfusion technique. Gastroenterology. 1970 Mar;58(3):321–328. [PubMed] [Google Scholar]
  11. Haagen Nielsen O., Bondesen S. Kinetics of 5-aminosalicylic acid after jejunal instillation in man. Br J Clin Pharmacol. 1983 Dec;16(6):738–740. doi: 10.1111/j.1365-2125.1983.tb02254.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hardy J. G., Healey J. N., Lee S. W., Reynolds J. R. Gastrointestinal transit of an enteric-coated delayed-release 5-aminosalicylic acid tablet. Aliment Pharmacol Ther. 1987 Jun;1(3):209–216. doi: 10.1111/j.1365-2036.1987.tb00620.x. [DOI] [PubMed] [Google Scholar]
  13. Hardy J. G., Healey J. N., Reynolds J. R. Evaluation of an enteric-coated delayed-release 5-aminosalicylic acid tablet in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 1987 Aug;1(4):273–280. doi: 10.1111/j.1365-2036.1987.tb00627.x. [DOI] [PubMed] [Google Scholar]
  14. Järnerot G. Newer 5-aminosalicylic acid based drugs in chronic inflammatory bowel disease. Drugs. 1989 Jan;37(1):73–86. doi: 10.2165/00003495-198937010-00005. [DOI] [PubMed] [Google Scholar]
  15. Klotz U. Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. Clin Pharmacokinet. 1985 Jul-Aug;10(4):285–302. doi: 10.2165/00003088-198510040-00001. [DOI] [PubMed] [Google Scholar]
  16. Klotz U., Maier K. E., Fischer C., Bauer K. H. A new slow-release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease. Biopharmaceutic and clinical pharmacokinetic characteristics. Arzneimittelforschung. 1985;35(3):636–639. [PubMed] [Google Scholar]
  17. Layer P., Chan A. T., Go V. L., DiMagno E. P. Human pancreatic secretion during phase II antral motility of the interdigestive cycle. Am J Physiol. 1988 Feb;254(2 Pt 1):G249–G253. doi: 10.1152/ajpgi.1988.254.2.G249. [DOI] [PubMed] [Google Scholar]
  18. Layer P., Go V. L., DiMagno E. P. Fate of pancreatic enzymes during small intestinal aboral transit in humans. Am J Physiol. 1986 Oct;251(4 Pt 1):G475–G480. doi: 10.1152/ajpgi.1986.251.4.G475. [DOI] [PubMed] [Google Scholar]
  19. Layer P., Jansen J. B., Cherian L., Lamers C. B., Goebell H. Feedback regulation of human pancreatic secretion. Effects of protease inhibition on duodenal delivery and small intestinal transit of pancreatic enzymes. Gastroenterology. 1990 May;98(5 Pt 1):1311–1319. [PubMed] [Google Scholar]
  20. Layer P., Peschel S., Schlesinger T., Goebell H. Human pancreatic secretion and intestinal motility: effects of ileal nutrient perfusion. Am J Physiol. 1990 Feb;258(2 Pt 1):G196–G201. doi: 10.1152/ajpgi.1990.258.2.G196. [DOI] [PubMed] [Google Scholar]
  21. Layer P., Zinsmeister A. R., DiMagno E. P. Effects of decreasing intraluminal amylase activity on starch digestion and postprandial gastrointestinal function in humans. Gastroenterology. 1986 Jul;91(1):41–48. doi: 10.1016/0016-5085(86)90436-1. [DOI] [PubMed] [Google Scholar]
  22. Mardini H. A., Lindsay D. C., Deighton C. M., Record C. O. Effect of polymer coating on faecal recovery of ingested 5-amino salicylic acid in patients with ulcerative colitis. Gut. 1987 Sep;28(9):1084–1089. doi: 10.1136/gut.28.9.1084. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Meyer J. H., Elashoff J., Porter-Fink V., Dressman J., Amidon G. L. Human postprandial gastric emptying of 1-3-millimeter spheres. Gastroenterology. 1988 Jun;94(6):1315–1325. doi: 10.1016/0016-5085(88)90669-5. [DOI] [PubMed] [Google Scholar]
  24. Myers B., Evans D. N., Rhodes J., Evans B. K., Hughes B. R., Lee M. G., Richens A., Richards D. Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut. 1987 Feb;28(2):196–200. doi: 10.1136/gut.28.2.196. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Norlander B., Gotthard R., Ström M. Pharmacokinetics of a 5-aminosalicylic acid enteric-coated tablet and suppository dosage form. Aliment Pharmacol Ther. 1989 Aug;3(4):333–342. doi: 10.1111/j.1365-2036.1989.tb00220.x. [DOI] [PubMed] [Google Scholar]
  26. Norlander B., Gotthard R., Ström M. Pharmacokinetics of a 5-aminosalicylic acid enteric-coated tablet in patients with Crohn's disease or ulcerative colitis and in healthy volunteers. Aliment Pharmacol Ther. 1990 Oct;4(5):497–505. doi: 10.1111/j.1365-2036.1990.tb00496.x. [DOI] [PubMed] [Google Scholar]
  27. Rasmussen S. N., Bondesen S., Hvidberg E. F., Hansen S. H., Binder V., Halskov S., Flachs H. 5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans. Gastroenterology. 1982 Nov;83(5):1062–1070. [PubMed] [Google Scholar]
  28. Rijk M. C., van Schaik A., van Tongeren J. H. Disposition of 5-aminosalicylic acid by 5-aminosalicylic acid-delivering compounds. Scand J Gastroenterol. 1988 Jan;23(1):107–112. doi: 10.3109/00365528809093858. [DOI] [PubMed] [Google Scholar]
  29. Riley S. A., Mani V., Goodman M. J., Herd M. E., Dutt S., Turnberg L. A. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology. 1988 Jun;94(6):1383–1389. doi: 10.1016/0016-5085(88)90677-4. [DOI] [PubMed] [Google Scholar]
  30. Riley S. A., Tavares I. A., Bennett A., Mani V. Delayed-release mesalazine (5-aminosalicylic acid): coat dissolution and excretion in ileostomy subjects. Br J Clin Pharmacol. 1988 Aug;26(2):173–177. doi: 10.1111/j.1365-2125.1988.tb03383.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Rolston D. D., Kelly M. J., Borodo M. M., Dawson A. M., Farthing M. J. Effect of bicarbonate, acetate, and citrate on water and sodium movement in normal and cholera toxin-treated rat small intestine. Scand J Gastroenterol. 1989 Jan;24(1):1–8. doi: 10.3109/00365528909092231. [DOI] [PubMed] [Google Scholar]
  32. Staerk Laursen L., Stokholm M., Bukhave K., Rask-Madsen J., Lauritsen K. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. Gut. 1990 Nov;31(11):1271–1276. doi: 10.1136/gut.31.11.1271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Wingate D. L., Sandberg R. J., Phillips S. F. A comparison of stable and 14 C-labelled polyethylene glycol as volume indicators in the human jejunum. Gut. 1972 Oct;13(10):812–815. doi: 10.1136/gut.13.10.812. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. van Hogezand R. A., van Hees P. A., van Gorp J. P., van Lier H. J., Bakker J. H., Wesseling P., van Haelst U. J., van Tongeren J. H. Double-blind comparison of 5-aminosalicylic acid and acetyl-5-aminosalicylic acid suppositories in patients with idiopathic proctitis. Aliment Pharmacol Ther. 1988 Feb;2(1):33–40. doi: 10.1111/j.1365-2036.1988.tb00668.x. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES